Chronic myeloid leukemia in a pediatric population in the Congo

Yıl 2017, Cilt: 4 Sayı: 3, 27 - 29, 31.03.2017

Lydie Ngolet Jenny Guelongo Okouango Ova Alexis Elira Dokekias

https://doi.org/10.17546/msd.299108

Öz

Objective: Chronic myeloid leukemia is a rare hematological malignant disorder among children and adolescents for which data are scare in Africa. The aim of the study is to report clinical, biological feature of children with chronic myeloid leukemia. Additionally, describing cytogenetic response to imatinib and adherence of children to the drug. Patients and Methods: A retrospective study was carried out from January 2007 to December 2016 (10 years) in the department of Hematology at the Teaching Hospital in Brazzaville.  Four of 52 patients admitted during the period for chronic myeloid leukemia, were children. We collected data from these children’s medical records for analysis. Results: They were four adolescents (2 boys and 2 girls) with a median age of 13.75 years at the time of diagnosis (range 11.2 and 16 years) that presented at the chronic phase of the  the chronic myeloid leukemia. Delay diagnosis was 4 months. All adolescents presented with a voluminous splenomegaly (median size: 16.75 cm) and high white blood cells count: 133.37G/L (range: 60.7 and 219 G/L). The response to imatinib was poor. None patient was adherent to the treatment. Conclusion: Chronic myeloid leukemia in children in the Congo is rare. Abdominal pain and voluminous splenomegaly are the main finding symptoms of the malignancy. Despite the delayed diagnosis of the disease, children present at chronic phase. The response to imatinib is poor as children are not adherent to the treatment.

Anahtar Kelimeler

children, children, chronic myeloid leukemia

Kaynakça

• 1. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children previously untreated chronic myelogenous leukemia in early chronic phase. Results of the French national Phase IV trial. J Clin Oncol.2011; 29: 2827-32.
• 2. Krumbholz M, KarlvM, Tauer JT, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia genes chromosomes. Cancer 2012; 51(11): 1045-53.
• 3. Hijiya N, Schultz KR, Metzler M, Millot F, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016; 127(4): 392-9.
• 4. Fall S, Ndiaye FSD, Dior OD, Sall AF, et al. Leucémie myeloide chronique des sujets jeunes: expérience dans une unité d’hématologie Clinique au Sénégal. Revue d’oncologie hématologie pédiatrique. 2015; 3 : 170-4.
• 5.S. O’ Brien, E Berman, H Borghuei, et al. NCCN clinical practice guidelines in oncology. I Natl Compr Cancer Netw. 2009; 7: 987-1020
• 6. El-Affy M, Alaa M, Haddad AL and Ahmed DH. Managelent of chronic myelogenous leukemia in the pediatric age group: imatinib mesylate or SCT. Journal of the Egyptian Nat. Cancer Inst. 2010; 22(4): 227-32.
• 7. Raut L, Bohara VV, Ray SS, Charkrabati P and Chaudhuri V. Chronic myeloid leukemia in children and adolescent: A single center experience from Eastern India. South Asian J. Cancer. 2013; 2(4): 260-4.
• 8. Ngolet LO, Kocko I, Galiba Atipo Tsiba O, et al. Imatinib mesylate in chronic myelogenous leukemia : a Congolese experience. EAMJ. 2016; 93(9): 118- 122.
• 9. Diallo DA,Cissoko LS,Cissoko Y, Diallo Y, Baby M et al. Epidémiologie actuelle des hémopathies malignes dans les services d’hématologie oncologie médicale et de médecine interne de l’hôpital du Point G, Bamako, Mali. Mali Médical. 2005; 20 (4):1-8.
• 10. S. Noens, M.R Van Liende, R De Bock et al. Prevalence, determinants, and outcomes of non adherence to imatinib therapy in patient with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 22 (113): 5401-11.